Getting Started

How Retatrutide Works

Whether you have seen retatrutide mentioned in news coverage of weight-loss medication or are following its development from clinical trials towards possible approval, this guide explains what retatrutide is, how it appears to work in the body, what the early trial data show, and where UK availability currently stands. LetsLoseWeight is an independent comparison site; we are not affiliated with any pharmacy or provider, and we do not sell or prescribe medication.

Important: Retatrutide is an investigational medicine. As of the last review date above, it is not licensed by the MHRA and is not available from regulated UK pharmacies. Anyone offering retatrutide for sale in the UK outside a registered clinical trial is doing so unlawfully. This guide is informational and does not promote use of retatrutide.

What is retatrutide?

Retatrutide is an experimental once-weekly injection developed by Eli Lilly. It is being studied for weight management, type 2 diabetes, sleep apnoea and metabolic dysfunction-associated steatohepatitis (formerly NAFLD). Unlike Wegovy or Mounjaro — which are already licensed in the UK — retatrutide has not yet completed phase 3 trials and is not yet approved by any major medicines regulator at the time of this guide's last review.

Retatrutide is part of a wider trial programme called TRIUMPH. The phase 2 results in adults with obesity were published in the New England Journal of Medicine in 2023 (Jastreboff et al., 2023). Phase 3 trials are ongoing.

How retatrutide is designed to work

Retatrutide is a triple receptor agonist. It is designed to activate three different hormone receptors involved in appetite regulation, blood sugar control and energy use:

  • GLP-1 (glucagon-like peptide-1)
  • GIP (glucose-dependent insulinotropic polypeptide)
  • Glucagon

The first two receptors — GLP-1 and GIP — are the same pair targeted by Mounjaro (tirzepatide). The third — glucagon — is what makes retatrutide structurally different. In context, that combination is intended to do four things.

1. Reduce appetite (GLP-1 and GIP action)

Like other GLP-1-class medicines, retatrutide is thought to reduce hunger by acting on appetite centres in the brain, particularly the hypothalamus.

2. Increase fullness after eating (GLP-1 action)

Slowed gastric emptying makes meals feel more filling, with the feeling of fullness lasting longer.

3. Improve blood sugar control (GLP-1 and GIP action)

Both GLP-1 and GIP stimulate insulin release in a glucose-dependent way, lowering blood sugar after meals while keeping the risk of hypoglycaemia low when used alone.

4. Increase energy expenditure (glucagon action)

This is the part that distinguishes retatrutide. Glucagon receptor activation is thought to increase the body's resting energy use — i.e. how many calories the body burns at rest — and to promote breakdown of stored fat in the liver. The clinical implication, if borne out in larger trials, is that retatrutide may achieve weight loss not only by reducing how much someone eats but also by modestly increasing how much energy they burn.

This third mechanism is also why retatrutide is being studied for fatty liver disease alongside obesity.

What the trial data show so far

The phase 2 retatrutide obesity trial enrolled adults with obesity but without type 2 diabetes. After 48 weeks, average weight loss was approximately:

  • 8.7% with the 1mg dose
  • 17.1% with 4mg
  • 22.8% with 8mg
  • 24.2% with 12mg

The placebo group lost an average of around 2.1% over the same period (Jastreboff et al., NEJM 2023). All participants also followed lifestyle interventions.

These are phase 2 results in a relatively small population over less than a year. They look promising compared with existing GLP-1 medicines, but several caveats apply:

  • Phase 2 results often look better than phase 3. Larger, longer trials in more diverse populations sometimes show smaller average effects.
  • Side-effect profile is still being mapped out. Reported side effects in the trial were mostly gastrointestinal — similar to Mounjaro and Wegovy — but the full safety picture in long-term, real-world use will only become clear after phase 3 and post-marketing surveillance.
  • No head-to-head trial against Mounjaro has been published. Comparisons across trials with different protocols, populations and durations should be treated cautiously.

Where retatrutide stands in the UK

At the last review date for this guide, retatrutide is not licensed in the UK by the MHRA, not authorised for prescription, and not available from any regulated UK pharmacy. There is no NICE technology appraisal because there is nothing yet to appraise.

Phase 3 trials are ongoing as part of the TRIUMPH programme. If those trials succeed, retatrutide will need to:

  1. Receive marketing authorisation from the MHRA.
  2. Be assessed by NICE for NHS use (a separate process to MHRA licensing).
  3. Be listed by manufacturers and supplied through pharmacy distribution networks.

Each step adds time. Even with a successful phase 3 readout, retatrutide is unlikely to be widely available privately in the UK in the immediate term, and longer still on the NHS.

For an up-to-date overview of UK access, see our Retatrutide UK page.

Risks of buying retatrutide outside regulated channels

Because retatrutide is not licensed, anyone offering it for sale in the UK is doing so outside the regulated supply chain. That carries real risks:

  • Counterfeit product — the vials may not contain retatrutide, or may contain incorrect doses or contaminants.
  • No clinical oversight — no prescriber assessment, no follow-up, no safety net if something goes wrong.
  • Legal risk — selling unlicensed prescription medicines is unlawful in the UK, and importing them for personal use without a prescription falls into a grey area at best.
  • No insurance protection — if an unregulated product harms you, recourse is extremely limited.

The MHRA has warned consumers about the risks of buying weight-loss medication from unregulated sources. The same warning applies — with extra force — to medicines that have not been approved at all.

Frequently asked questions

When will retatrutide be available in the UK?
There is no published date. The earliest realistic possibility, assuming phase 3 trials succeed without delay, is sometime after MHRA approval, which itself follows trial completion and review. As of this guide's last review, that approval has not been granted.

Is retatrutide better than Mounjaro?
The phase 2 retatrutide trial showed larger average weight loss than has been reported for tirzepatide in its own pivotal trials, but the comparison is across studies, not within one. Phase 3 results and head-to-head trials would be needed before any reliable comparison can be made.

Can I get retatrutide on a clinical trial?
Possibly. The TRIUMPH trial programme is recruiting participants in some countries. For UK trial sites, see the National Institute for Health and Care Research's Be Part of Research portal.

Is retatrutide the same as Mounjaro?
No. Mounjaro is tirzepatide, a dual GIP/GLP-1 agonist already licensed in the UK. Retatrutide is a different molecule that adds a third mechanism (glucagon receptor activation) and is still in trials.

Next steps

Sources

This guide is for general information only and is not a substitute for professional medical advice. Retatrutide is not currently approved or available in the UK outside clinical trials.

Get weekly weight loss tips

Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.

Subscribe free
Back to Guides
How Retatrutide Works: Triple Agonist Trial Data | LetsLoseWeight